Introduction
Randomized trials have established the benefit of carotid endarterectomy (CEA) in reducing the risk for stroke in patients with moderate to severe (!50%) symptomatic carotid artery stenosis [1-3] and to a less extent in those with asymptomatic (!60%) carotid stenosis [4, 5] . CEA, however, is associated with short-term risks for stroke or death of about 3% in asymptomatic patients [6] and 5% in symptomatic patients [7] .
As compared with CEA, carotid angioplasty and stenting (CAS) is associated with the following benefits: it usually avoids the need for general anaesthesia and its complications; it avoids neck incision and subsequent cranial and cutaneous damage; it may be associated with lower costs by reducing recovery time and hospital stay; and it may be the only treatment option in patients who are at high risk after surgery because of co-morbidity. CAS also carries risks for stroke and local complications, however (Table 1) [8 ] . The technique has been evaluated in patients with symptomatic or asymptomatic carotid ste-nosis who were also eligible for CEA, and in patients who were considered not suitable for CEA because of a perceived high surgical risk. In 2005 a Cochrane review of five trials and another meta-analysis of six trials did not identify any significant difference in safety and efficacy between CEA and carotid angioplasty with or without stenting, and did not support a change from the recommendation of CEA as standard treatment for carotid stenosis [9, 10] . Given the small number of patients, however, confidence intervals were wide, and it was therefore not possible to rule out a potentially important advantage or disadvantage of one treatment over the other. Since the review was published, results from several major trials and large registries have been reported [11 ] . and Vertebral Artery Transluminal Angioplasty Study) study started in 1992 and randomized 504 patients (mainly with symptomatic carotid stenosis) to receive either angioplasty or CEA [12] . There was no difference in the rate of death or any stroke within the 30 days after treatment between CAS and CEA (10.0% versus 9.9%), but the events rate in the CEA group was higher than that reported in other randomized trials, At 1 year severe restenosis was more common after endovascular treatment (14% versus 4%, P < 0.0001). Other early trials were small or were stopped because of poor outcomes in the angioplasty group [9, 10, 13] .
EVA-3S (Endarterectomy Versus Angioplasty in
Patients with Severe Symptomatic Carotid Stenosis) is a French multicentre, noninferiority randomized trial with institutional funding designed to compare CAS with CEA in patients with symptomatic carotid stenosis !60% [measured using the NASCET (North American Symptomatic Carotid Endarterectomy Trial) method] whom investigators believed to be suitable for both surgery and CAS [14 ] . Interventional physicians were required to document at least 12 CAS procedures before participating in the study. Initially, CAS could be performed with or without the use of cerebral protection. After 80 patients had been treated in the CAS arm, however, the safety committee recommended use of cerebral protection devices systematically because of an increased 30-day risk for stroke in patients treated with CAS without cerebral protection [odds ratio (OR) 3.9, 95% confidence interval 0.9-16.7]. The trial was stopped prematurely after the inclusion of 527 patients for reasons of both safety and futility. The 30-day incidence of any stroke or death was 3.9% (95% CI 2.0-7.2%) after CEA and 9.6% (95% CI 6.4-14.0%) after CAS (relative risk 2.5, 95% CI 1.2-5.1). The 30-day incidence of disabling stroke or death was 1.5% (95% CI 0.5-4.2%) after CEA and 3.4% (95% CI 1.7-6.7%) after CAS (relative risk 2.2, 95% CI 0.7-7.2). At 6 months, the incidence of any stroke or death was 6.1% after CEA and 11.7% after CAS (P ¼ 0.02). The rates of death and stroke at 1 and 6 months were lower with CEA than with CAS.
The multinational (Germany, Austria, Switzerland) SPACE (Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy) trial randomized 1200 patients [15 ] . Once again, the aim was to investigate whether CAS was not inferior to CEA in patients (aged 50 years or older) with symptomatic carotid stenosis [>70% according to the European Carotid Surgical Trial (ECST) method or >50% according to the NASCET method] and who were eligible for both methods. The primary investigator of each centre had to demonstrate 25 successful interventions before participation in the trial, whereas secondary investigators received a preliminary certificate after 10 interventions. The study steering committee opted to stop recruitment after a second interim analysis, because the probability that the trial would achieve its objectives was low and might only have been achieved if 1200-1800 further patients had been recruited. Of the CAS patients 26.6% were Carotid stenting Touzé et al. 57 treated using a cerebral protection device. The rate of ipsilateral stroke and death between randomization and day 30 after treatment (primary end-point) was 6.84% with CAS and 6.34% with CEA group (absolute difference 0.51%, 90% CI À1.89% to þ2.91%). The upper limit of the 90% CI of the absolute risk reduction exceeded the predefined noninferiority margin of 2.5%; hence, SPACE was unable to prove the noninferiority of CAS compared with CEA in treating patients with symptomatic carotid stenosis. The authors concluded that the results of this trial did not justify the widespread use of CAS for treatment of carotid stenosis.
Using the same end-point as was used in EVA-3S, the rates of any stroke or death within 30 days were 7.7% (95% CI 5.7-10.1%) in the CAS group and 6.5% (95% CI 6.3-13.8%) in the CEA group.
The 30-day rate of severe events (i.e. disabling stroke or death) in patients treated by CAS was slightly higher in SPACE (4.8%) than in EVA-3S (3.4%), but the CIs overlap. The 30-day rate of stroke or death in the surgical group was lower in EVA-3S (3.9%) than in SPACE (6.5%), resulting in a greater difference between both groups in EVA-3S, in which it reached the level of statistical significance [20 ] .
An updated meta-analysis of eight trials identified a significant 41% relative increase in risk for any stroke and death within 30 days after treatment in the endovascular treatment group compared with the surgical group (OR 1.41, 95% CI 1.07-1.87; P ¼ 0.016) [11 ,21] . Significant heterogeneity was identified in this analysis, however (P ¼ 0.016). The facts that some trials included asymptomatic patients and that endovascular technique has changed over time could explain this heterogeneity. Looking at patients with symptomatic carotid stenosis only, results were similar; CAS was associated with a nonsignificant increase in risk for any stroke or death (OR 1.33, 95% CI 0.97-1.82; P ¼ 0.078; P for heterogeneity ¼ 0.078) and disabling stroke and death (OR 1.28, 95% CI 0.85-1.93; P ¼ 0.23; P for heterogeneity ¼ 0.23) [21] .
Patients with asymptomatic carotid stenosis who are good surgical candidates
Asymptomatic carotid stenosis !50% is common, with a prevalence of 7% in men and 5% in women older than 65 years [22 ] . The overall benefit of CEA in asymptomatic patients is marginal (absolute reduction in risk for stroke only about 1%/year versus >8%/year during the 2 years following a stroke or a transient ischaemic attack in patients with !70% symptomatic carotid stenosis) and can be achieved with a perioperative risk for stroke or death 3%. In patients at such low surgical risk [5,6], CAS could be considered an alternative to surgery as long as it is proven to be equivalent to CEA. Unfortunately, CAS has been compared with CEA in only one small trial, which randomized 85 patients [18] . There was no stroke or death in either group (Table 2) . The safety of CAS has also been evaluated in several case series (Table 3 ) [23 ,24 ,25,26,27 ,28-53] but in the absence of a CEA group no conclusion can be drawn regarding any advantage of CAS over CEA in these patients. Moreover, in those studies the periprocedural risk for stroke or death was consistently over the 3% bar established in the large CEA trials (Table 3) . Therefore, there are insufficient data to support the preferential use of CAS over CEA in asymptomatic patients who are good candidates for surgery [8 ] .
Patients at perceived high surgical risk
CAS has mainly been evaluated in patients at high perceived risk for complications from open surgery in one small randomized trial [19] and many registries (Table 3) . Commonly cited factors associated with greater surgical risk are anatomical factors such as surgically inaccessible lesions, prior CEA or neck irradiation, old age, contralateral carotid occlusion, and medical comorbidities (e.g. severe congestive heart failure, recent unstable angina, recent acute myocardial infarction, or two or more unrevascularized coronary vessels). Not all of these factors were exclusion criteria for the large CEA trials, however, and there is considerable variability in the definition of high risk among those studies. Most studies have included both symptomatic and asymptomatic patients with separate reporting of outcomes for symptomatic patients in only a few of them. Moreover, at present there is no proven high-risk subgroup that enjoys a greater magnitude of benefit with carotid revascularization, and it is critical to note that high surgical risk does not mean high risk for stroke under medical therapy [22 ] . Finally, it is likely that co-morbidities that are associated with a greater perioperative risk with CEA also increase the periprocedural risk with CAS.
The SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy) trial [19] was a randomized noninferiority trial comparing CEA with CAS with cerebral protection. It was conducted in patients with !80% carotid stenosis (71% of patients were asymptomatic) satisfying at least one highrisk criterion for surgery. The study was prematurely terminated after recruiting 334 patients because of decreased enrollment. At the end of 1 year the cumulative incidence of primary end-points (death, stroke, or myocardial infarction, including the perioperative period) in the symptomatic patients was 12.2% in the CAS group and 20.1% in the CEA group (P ¼ 0.05). These figures are high but were in keeping with the higher risk group. In the asymptomatic patients, primary end-points occurred in 9.9% in the CAS group and in 21.5% in the CEA group (30-day perioperative stroke, myocardial infarction, or death: 4.8% versus 9.8%, P ¼ 0.09). In patients with symptomatic carotid stenosis the cumulative incidence of the primary end-point at 1 year was 16.8% among those who received a stent as compared with 16.5% among those who underwent CEA (30-day perioperative stroke, myocardial infarction, or death: 2.1% versus 9.3%, P ¼ 0.18). The investigators drew the conclusion that, in patients with severe carotid stenosis and coexisting con-ditions, CAS with the use of protection device is not inferior to CEA.
A major issue was the absence of a medical control group, precluding any conclusion regarding the superiority of CEA or CAS over medical treatment alone in this particular population. Indeed, it is uncertain whether those patients (mainly asymptomatic) were also at high risk for stroke on medical therapy alone. Thus, if the risk for stroke on medical treatment in SAPPHIRE patients is in fact similar to that in more conventional patients, and given the high rate of periprocedural complications observed in both arms, it is possible that neither technique would have exhibited any benefit if they had been compared with medical therapy. In addition, the results were heavily influenced by coronary events, which -in contrast to all previous carotid surgery trials -were included in the primary end-point. When myocardial infarctions were removed, the primary end-point occurred in 5.5% with CAS and 8.4% with CEA (P ¼ 0.36). The risk for a periprocedural coronary event might be less in patients treated by CAS than in those treated by surgery, although in SAPPHIRE the difference did not reach statistical significance (2.4% versus 6.1%, P ¼ 0.10). Thus, extending this reasoning, the practical implication of this trial might be that patients with asymptomatic carotid stenosis (in whom the risk for ipsilateral stroke is low and in whom there should be 3% perioperative risk) and at high surgical risk should be treated with neither surgery nor CAS.
Many registries have been established to acquire marketing or postmarketing approval (Tables 3 and 4 ) [19,23 ,24 ,25,26,27 ,28-53] . Overall, the 30-day risks for stroke or death in registries were similar to or slightly greater than those observed in randomized trials that compared CAS with CEA. These registries did not include a control group, and therefore some sponsors used historical weighted estimates of stroke or death of up to 15% at 30 days after CEA [27 ] . Such a comparison is questionable, however, because estimates are not based on direct evaluation. More importantly, looking at symptomatic and asymptomatic patients separately, the 30-day perioperative risks are overall greater than those observed in CEA trials [1-5, 54, 55] . Several postmarketing surveillance registries are ongoing [8 ] .
Embolic protection devices
The development of devices to protect against embolism during the CAS procedure potentially represents an important advance. A systematic review of nonrandomized case series showed that the use of cerebral protection devices appears to reduce thromboembolic complications during CAS (3.7% without cerebral protection versus 0.5% with protection, P < 0.0001) [56] . In addition, such protection devices were shown to reduce the incidence of new, mostly asymptomatic, ischaemic lesions on diffusion-weighted magnetic resonance imaging performed within the 48 h after CAS [57] . Finally, in the EVA-3S French trial [58] the safety committee recommended stopping unprotected CAS because of an increased 30-day rate of stroke (4/15 versus 5/58; OR 3.9, 95% CI 0.9-16.7). No such finding was reported in the SPACE trial, in which the rate of periprocedural complications was unrelated to the use of protection device (OR 1.09, 95% CI 0.53-2.25) [15 ] . There are still no data from randomized studies comparing CAS with or without cerebral protection, however. Also, because the protective device must pass through the arterial stenosis, they themselves might cause complications. Possible modes of failure include inability to deliver or deploy the device, inadvertent device-induced vessel injury or embolization, cerebral ischaemia caused by device-induced carotid occlusion, incomplete capture or retrieval of embolic debris, or 60 Cerebrovascular disease embolization into proximal branches (such as the ophthalmic artery) that might supply collaterals to the intracranial circulation. Despite this uncertainty, cerebral protection devices have become rather popular with interventionists.
Role of physician experience
Several observational studies have suggested that inexperience in CAS could be associated with increased risk for periprocedural complications, and several professional societies have reported guidelines for CAS training [30, 44, 59] . This assumption is mainly based on temporal trends showing a certain decrease in risk with time [30, 59] , however, rather than on direct assessment of the relationships between risk and the number of procedures performed by operators. Moreover, data are conflicting, with studies showing no correlation between physician/centre experience and perioperative risk [14 ,60] . In the recent CAPTURE (Carotid Acculink/ Accunet Post Approval Trial to Uncover Rare Events) registry, the 30-day rates of stroke, death, or myocardial infarction did not significantly differ among the three operator experience levels (5.3%, 6.0% and 7.4%; P ¼ 0.31) from most to least experienced [24 ] . It is also likely, however, that physicians/centres that perform large numbers of CAS procedures receive more complicated patients, which could bias the risk. In the EVA-3S trial [14 ] 15.8% patients were treated by interventional physicians who had performed more than 50 CAS procedures, 45.4% by physicians who had performed 50 or fewer procedures, and 38.8% by physicians still in procedural training. The 30-day risks for stroke or death for these three groups were 12.2%, 11.0% and 7.1%, respectively (P ¼ 0.49).
Conclusion
According to our present knowledge, CAS is not safer than CEA and neither does it provide better outcomes, at least in the short term in patients with carotid stenosis and who are good surgical candidates. Those patients should be informed that CEA is still the standard treatment for prevention of ipsilateral ischaemic stroke (see the American Heart Association recommendations summarized in Table 5 [61]). Although CAS may be an acceptable option in selected patients, much remains to be done to identify those patients who will benefit more from CAS than from CEA, and to identify the factors related to patient characteristics, arterial anatomy, operator experience, and the procedure itself that are associated with a high or low risk for stroke after CAS. Long-term follow-up data from the recent SPACE and EVA-3S trials are not yet available. In particular, the rates of restenosis after CEA and CAS may have an impact on decision making, despite re-stenosis being asymptomatic in most cases. Several randomized trials are currently ongoing or are about to start: ICCS (International Carotid Stenting Study) [62] , ACT-I (Asymptomatic Carotid Trial-I; http:// www.act1trial.com), ACST-2 (Asymptomatic Carotid Surgery Trial-2), and TACIT (Transatlantic Asymptomatic Carotid Intervention Trial) [63] .
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(1)
For patients with recent TIA or ischaemic stroke within the last 6 months and ipsilateral severe (70-99%) carotid artery stenosis, CEA by a surgeon with a perioperative morbidity and mortality rate of <6% is recommended (class I, level A) (2)
For patients with recent TIA or ischaemic stroke and ipsilateral moderate (50-69%) carotid stenosis, CEA is recommended, depending on patient-specific factors such as age, sex, co-morbidities and severity of initial symptoms (class I, level A) (3)
When degree of stenosis is <50%, there is no indication for CEA (class III, level A) (4) When CEA is indicated, surgery within 2 weeks rather than delayed surgery is suggested (class IIa, level B) (5)
Among patients with symptomatic severe stenosis (>70%) in whom the stenosis is difficult to access surgically, medical conditions are present that greatly increase the risk for surgery, or when other specific circumstances exist such as radiation-induced stenosis or restenosis after CEA, CAS is not inferior to CEA and may be considered (class IIb, level B) (6) CAS is reasonable when performed by operators with established periprocedural morbidity and mortality rates of 4-6%, similar to that observed in trials of CEA and CAS (class IIa, level B)
Summarized are the American Heart Association/American Stroke Association recommendations for revascularization in symptomatic patients [61] . CAS, carotid angioplasty and stenting; CEA, carotid endarterectomy; TIA, transient ischaemic attack.
